Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection

Transplantation. 2017 Oct;101(10):2419-2428. doi: 10.1097/TP.0000000000001834.

Abstract

Background: Sensitization to HLA remains a significant immunologic barrier to successful transplantation. Identifying immune mechanisms responsible for antibody-mediated rejection (AMR) is an important goal. Here, we explored the possibility of predicting the risk for AMR by measuring mRNA transcripts of AMR-associated genes in plasma exosomes from kidney transplant patients.

Methods: Total RNA was extracted from exosomes purified from 152 ethylenediaminetetraacetic acid-plasma samples of 64 patients (18 AMR, 8 cell-mediated rejection [CMR], 38 no rejection in desensitized [DES] and non-DES control groups) for reverse transcription into cDNA, preamplification and then real time quantitative polymerase chain reaction (qPCR) for 21 candidate genes. The mRNA transcript levels of each gene were calculated. Comparisons were made among 4 patient groups for each gene and also for a gene combination score based on selected genes.

Results: Among 21 candidate genes, we identified multiple genes (gp130, CCL4, TNFα, SH2D1B, CAV1, atypical chemokine receptor 1 [duffy blood group]) whose mRNA transcript levels in plasma exosomes significantly increased among AMR compared with CMR and/or control patients. A gene combination score calculated from 4 genes of gp130, SH2D1B, TNFα, and CCL4 was significantly higher in the AMR than the CMR (P < 0.0001) and no rejection control groups (P < 0.01 vs DES control, P < 0.05 vs non-DES control).

Conclusions: Our results suggest that plasma exosomes may contain information indicating clinical conditions of kidney transplant patients. mRNA transcript profiles based on gp130, SH2D1B, TNFα, and CCL4 in plasma exosomes may be used to predict on-going and/or imminent AMR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Chemokine CCL4 / genetics
  • Cytokine Receptor gp130 / genetics
  • Exosomes / genetics
  • Exosomes / metabolism*
  • Female
  • Gene Expression Profiling / methods
  • Genetic Markers
  • Graft Rejection / blood*
  • Graft Rejection / genetics
  • Graft Rejection / immunology
  • HLA Antigens / immunology*
  • Histocompatibility*
  • Humans
  • Isoantibodies / blood*
  • Kidney Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • RNA, Messenger / blood*
  • RNA, Messenger / genetics
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Risk Assessment
  • Risk Factors
  • Transcription Factors / genetics
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • CCL4 protein, human
  • Chemokine CCL4
  • Genetic Markers
  • HLA Antigens
  • IL6ST protein, human
  • Isoantibodies
  • RNA, Messenger
  • SH2D1B protein, human
  • Transcription Factors
  • Tumor Necrosis Factor-alpha
  • Cytokine Receptor gp130